Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease.

about

Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis.EFFECT OF MATERNAL HIGH-FAT DIET ON KEY COMPONENTS OF THE PLACENTAL AND HEPATIC ENDOCANNABINOID SYSTEM.

P2860

Q33631151-DA982F1F-C936-433D-9E51-EF7C3F9EA1D4 Q47402428-530D878A-D6CE-423A-9D95-3B247EB4CAEE

P2860

Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease.

Item

http://www.wikidata.org/entity/Q51276156

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Serum levels of endocannabinoi ...... alcoholic fatty liver disease.

@en

Serum levels of endocannabinoi ...... alcoholic fatty liver disease.

@nl

type

Item

label

Serum levels of endocannabinoi ...... alcoholic fatty liver disease.

@en

Serum levels of endocannabinoi ...... alcoholic fatty liver disease.

@nl

prefLabel

Serum levels of endocannabinoi ...... alcoholic fatty liver disease.

@en

Serum levels of endocannabinoi ...... alcoholic fatty liver disease.

@nl

P1476

Serum levels of endocannabinoi ...... alcoholic fatty liver disease.

@en

P2093

Alina Nemirovski

http://www.w3.org/2001/XMLSchema#string

Joseph Tam

http://www.w3.org/2001/XMLSchema#string

Muriel Webb

http://www.w3.org/2001/XMLSchema#string

Oren Shibolet

http://www.w3.org/2001/XMLSchema#string

Shahar Azar

http://www.w3.org/2001/XMLSchema#string

Shira Zelber-Sagi

http://www.w3.org/2001/XMLSchema#string

Zamir Halpern

http://www.w3.org/2001/XMLSchema#string

P2860

A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol

Activation of the peripheral endocannabinoid system in human obesity

Leptin-regulated endocannabinoids are involved in maintaining food intake

Dietary linoleic acid elevates endogenous 2-AG and anandamide and induces obesity

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis.

Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease.

Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort

CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice

Obesity modifies the association between plasma phospholipid polyunsaturated fatty acids and markers of inflammation: the Multi-Ethnic Study of Atherosclerosis

P304

94-101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/OBY.21687

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27863097

http://www.w3.org/2001/XMLSchema#string

P921

endocannabinoids

Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease.

about

P2860

P2860

Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921